STAT News published a major investigation Monday July 20, 2026 reporting that LifeMD, a US telehealth company promoted by Novo Nordisk as a partner for Wegovy and Ozempic access, has pushed clinicians to see more patients and dispense GLP-1 prescriptions more rapidly while providing what former workers describe as minimal screening and follow-up. Five former employees and two lawsuits filed by former top leaders allege that providers at LifeMD were pressed to review up to 25 patient cases per hour based only on the electronic intake forms patients themselves filled out, translating to approximately two minutes per case. Novo Nordisk currently lists LifeMD on its website as a partner that offers 'legitimate medicine sourcing and patient support' for people seeking GLP-1 drugs. LifeMD strenuously denies the allegations. The reporting extends the June-July concern set documented by the JAMA secret-shopper study (45 of 49 online sellers wrote semaglutide or tirzepatide prescriptions within a day with limited clinical oversight, July 7 digest coverage) and complements the peptide-telehealth-landscape reporting the site has tracked through 2026. The LifeMD story sits within the sprawling loosely-regulated GLP-1 telehealth industry that experts say has been boosted by Novo Nordisk and Eli Lilly as branded-drug demand expanded through 2025 and 2026.
STAT News' Pharmalot newsletter reported Wednesday-Thursday July 8-9, 2026 that the White House is reviewing three finalists to lead the FDA following the departure of the prior commissioner earlier in 2026: Heidi Overton, a policy adviser in the White House itself; Jeffrey Vacirca, an oncologist and health-system executive; and Stephen Ferrara, a health official at the Department of Defense. Axios first surfaced the shortlist on June 26; the July 8-9 STAT reporting confirmed the trio is under active White House review with a decision expected in the coming weeks. The peptide policy trajectory tracks through whichever nominee advances. FDA career-staff briefing documents released June 29-30 concluded all seven PCAC peptides have insufficient evidence for 503A eligibility, while HHS Secretary RFK Jr.'s public push points the other direction; the incoming commissioner will inherit an agency-vs-secretary tension around peptide compounding as the July 23-24 PCAC vote lands. The nominee will also inherit the pending Novo Nordisk-Vivani semaglutide-implant evaluation agreement, the Sandoz generic-tirzepatide ANDA acceptance from June 29, and the ongoing 503B GLP-1 exclusion rulemaking.
PolitiFact published a primer piece Wednesday July 1, 2026 titled 'A primer on retatrutide and compassionate use,' laying out the underlying facts of the STAT News June 23 disclosure for readers coming to the story after two weeks of political-controversy coverage. The primer format explained: what compassionate use is (the FDA's expanded-access single-patient IND pathway, 21 CFR 312 Subpart I, ~1,800 requests per year at 99%+ approval); what retatrutide is (Eli Lilly's investigational GLP-1/GIP/glucagon triple agonist, still in Phase 3, TRIUMPH-1 topline 28.3% mean weight loss at 12 mg over 80 weeks); the STAT News reporting timeline (June 23 initial scoop by Lizzy Lawrence, June 25 Senator Hassan letter, June 26 Rep. Ted Lieu press conference, June 29 White House pushback); and what remains unconfirmed (the patient's identity, Lilly's specific rationale for granting the compassionate-use request, whether the White House denial framing constitutes a categorical denial or a non-denial). PolitiFact did not confirm the patient's identity and did not issue a rating on any specific claim; the piece functions as fact-based reference material for the broader public conversation. The primer format is likely to circulate as the reference PolitiFact link for future stories on the case.
STAT News reporter Lizzy Lawrence broke a scoop late Monday June 29, 2026 disclosing that the FDA on Monday published the names of eight new panelists who will serve on the July 23-24 Pharmacy Compounding Advisory Committee reviewing seven peptides for 503A bulks list eligibility. The majority of new members are involved with businesses that promote and prescribe peptides, meaning they will be weighing rules changes that could materially benefit them. Specific named members include Bobby Harshbarger, a pharmacist and Tennessee state senator whose mother Rep. Diana Harshbarger (R-TN) is also a pharmacist and has formally urged Kennedy to convene the panel; and Dr. Gabriel Alizaidy, who charges $500 for 'peptide and hormone' consultations that include advice on 'where to safely get each peptide or compound.' UC Davis cell-biology professor Paul Knoepfler told STAT: 'It's concerning that several members of the newly formulated [committee] appear to sell unproven offerings including stem cells and peptides, sometimes both.' FDA rules permit experts with financial stakes to serve on advisory panels as long as the relationship is disclosed and the agency explains why the expertise outweighs the potential conflict. Parallel coverage ran in CNN, PBS NewsHour, Washington Times, and CP24.
STAT News' Pharmalittle column on Tuesday June 30, 2026 disclosed that US lawmakers are investigating whether several large pharmaceutical companies have been involved in clinical trials at Chinese sites that helped advance China's military capability. The investigation runs parallel to the BIOSECURE Act (passed 2024) restricting US biotech contracting with named Chinese CDMOs and gene-sequencing companies, and to the structural anxiety about Chinese scientific output that biotech executives flagged at BIO 2026 last week. The Insilico Medicine (Hong Kong-headquartered) + SK Biopharmaceuticals $2.5 billion AI-neuroimmune drug discovery pact announced June 22 at BIO 2026 opening sits inside this conversation, as do Chinese-API supply chains feeding US gray-market peptide vendors and the licensed-generic semaglutide flow from Indian and Chinese manufacturers post-March 2026 patent expiration. The lawmaker probe expands the regulatory aperture beyond the BIOSECURE Act's named-entity list toward broader scrutiny of US-China clinical-research cooperation. No specific drugmakers were publicly named in the Pharmalittle report.
STAT News' closing coverage of BIO 2026 in San Diego across two pieces, Alex Hogan's June 26 STATus Report and Damian Garde's June 25 key-takeaways feature, identified two organizing themes that emerged from the four-day convention. First, AI drug discovery shifted from investment-thesis territory to clinical-fact territory: Insilico Medicine's rentosertib (a TNIK inhibitor for idiopathic pulmonary fibrosis where both the target and the compound were identified by generative AI, not a human chemist) became the first peer-reviewed Phase IIa result for a fully AI-discovered drug when results were published in Nature Medicine in 2025 (60 mg once daily produced +98.4 mL mean FVC change versus -20.3 mL placebo across 71 patients). Second, biotech executives at BIO 2026 expressed structural anxiety about Chinese drug development that the industry's primary legislative response, the BIOSECURE Act, does not address: the concern is about the speed and depth of Chinese scientific output rather than about narrow IP or supply-chain risks. The convention's mood reportedly shifted notably from the depressed atmosphere at industry events in 2024-2025 (when capital markets were closed and FDA reviewer turnover was concerning) toward a more constructive engagement with the new operational reality.
In addition to the political escalation (Senator Hassan's June 25 letter to RFK Jr.; Rep. Ted Lieu's June 24 terminal-illness press conference; White House counterattacks against STAT reporter Lizzy Lawrence and Lieu), STAT News reported that 18 bioethics experts, obesity-medicine clinicians, and current and former US government health officials told the outlet that Eli Lilly's decision to grant compassionate-use access to retatrutide for a single 79-year-old patient with refractory obesity, obstructive sleep apnea, and pulmonary hypertension 'struck them as unusual.' The core question raised by the bioethics community: why Lilly would offer compassionate use for a single patient when obesity is a population-scale condition affecting more than 100 million Americans, when expanded-access programs are typically structured around treatment INDs or intermediate-size protocols for broader access, and when the standard pathway for obesity-drug access is trial enrollment (TRIUMPH-2 obesity+T2D and TRIUMPH-3 obesity+CVD remain open). Jamy Ard (chief science officer, Advocate Health) said compassionate use is typically reserved for terminal illness. The bioethics critique is separate from the Trump-recipient speculation and is likely the more durable framing of the case as it moves through congressional oversight.
Following STAT News reporter Lizzy Lawrence's June 23 scoop that the FDA and Eli Lilly granted compassionate-use retatrutide access to a 79-year-old patient on the application of NIH senior clinician Dr. Ranganath Muniyappa, the White House response intensified June 23-24. Senior deputy press secretary Kush Desai posted on X that 'this application was not for the President' but did not explicitly deny that Trump (who turned 80 on June 14) had separately applied. After Lawrence reported the non-denial, Desai publicly called her 'an unserious gossip columnist.' The White House rapid response team added: 'No, it wasn't President Trump — and you people are truly sick and deranged.' The escalation moves the story from a closed regulatory-access question to an active political controversy, with outlets including The Hill, IBTimes UK, Slate, MS NOW, Hello Magazine, Tech Times, and The New Republic running parallel coverage. Outside medical experts continue to question whether refractory obesity plus OSA plus pulmonary hypertension meets the FDA's compassionate-use threshold typically reserved for immediately life-threatening illness.
STAT News' June 24, 2026 BIO Readout column (Damian Garde, Allison DeAngelis) delivered behind-the-scenes detail on Eli Lilly's January 9, 2026 collaboration with AI startup Chai Discovery for biologics design, plus an update on the Lilly-Astellas joint bid for Sangamo Therapeutics assets in bankruptcy. The Chai Discovery deal deploys the company's Chai-2 zero-shot antibody design model (reportedly achieving double-digit experimental hit rates and full de novo design capability) plus a purpose-built generative AI model trained exclusively on proprietary Lilly data and tailored to Lilly's discovery workflows. Chai closed a $130 million Series B at $1.3 billion valuation in late 2025, eighteen months after launch. On the Sangamo front, Lilly is in line to acquire Sangamo's capsid delivery platform, zinc finger platform, modular integrase platform, and prion disease program ST-506 in the bankruptcy auction; Astellas is positioned to take Fabry disease asset isaralgagene civaparvovec. BIO 2026 runs June 22-25 at the San Diego Convention Center.
STAT News published an April 29 First Opinion piece arguing that the FDA's pending peptide reclassifications — driven by HHS Secretary RFK Jr.'s public enthusiasm for compounds like BPC-157 and GHK-Cu — risk reopening access to inadequately-tested compounds. The op-ed highlights specific safety concerns flagged in the FDA's original 2023 Category 2 designations: immunogenicity, impurities, and the absence of meaningful human clinical data. The piece is positioned as scientific-community pushback ahead of the July 23-24 PCAC meeting that will rule on seven peptides.
STAT's pharmaceutical roundup covers the FDA's expected move to allow compounding of previously banned peptides and the impact of the Iran conflict on global clinical trial recruitment.